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Abstract
Aims/hypothesis Although recent studies propose that epi-
genetic factors influence insulin expression, the regulation
of the insulin gene in type 2 diabetic islets is still not fully
understood. Here, we examined DNA methylation of the
insulin gene promoter in pancreatic islets from patients with
type 2 diabetes and non-diabetic human donors and related
it to insulin expression, HbA1c levels, BMI and age.
Methods DNA methylation was analysed in 25 CpG sites of
the insulin promoter and insulin mRNA expression was
analysed using quantitative RT-PCR in pancreatic islets from
nine donors with type 2 diabetes and 48 non-diabetic donors.
Results Insulin mRNA expression (p=0.002), insulin con-
tent (p=0.004) and glucose-stimulated insulin secretion (p=
0.04) were reduced in pancreatic islets from patients with type
2diabetescomparedwithnon-diabetic donors.Moreover, four
CpG sites located 234 bp, 180 and 102 bp upstream and 63 bp
downstream of the transcription start site (CpG −234, −180,
−102 and +63, respectively), showed increased DNA methyl-
ation in type 2 diabetic compared with non-diabetic islets
(7.8%, p=0.03; 7.1%, p=0.02; 4.4%, p=0.03 and 9.3%, p=
0.03, respectively). While insulin mRNA expression corre-
lated negatively (p<1×10
−6), the level of HbA1c correlated
positively (p≤0.01) with the degree of DNA methylation for
CpG −234, −180 and +63. Furthermore, DNA methylation
for nine additional CpG sites correlated negatively with
insulin mRNA expression (p≤0.01). Also, exposure to
hyperglycaemia for 72 h increased insulin promoter DNA
methylation in clonal rat beta cells (p=0.005).
Conclusions/interpretations This study demonstrates that
DNA methylation of the insulin promoter is increased in
patients with type 2 diabetes and correlates negatively with
insulin gene expression in human pancreatic islets.
Keywords Alpha cells.Beta cells.DNA methylation.
Epigenetic.Gene expression.Human.Hyperglycaemia.
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Abbreviations
ATF2 Activating transcription factor 2
CREB2 cAMP responsive element binding protein 2
PGC-1α Peroxisome proliferator-activated receptor
gamma coactivator 1-α
SNP Single-nucleotide polymorphism
TFBS Transcription factor binding site
TSS Transcription start site
Introduction
Type 2 diabetes is a multifactorial disease characterised by
chronic hyperglycaemia as a result of defects in insulin
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target tissues including skeletal muscle, adipose tissue and
liver. It is well established that genetic and non-genetic
factors influence susceptibility to type 2 diabetes. Recent
studies suggest that epigenetic factors, including DNA
methylation and histone modifications, may influence the
pathogenesis of type 2 diabetes [1–4]. Indeed, we have
recently shown that DNA methylation of the PPARGC1A
(encoding peroxisome proliferator-activated receptor γ,
coactivator 1 α [PGC-1α]) promoter is increased in
pancreatic islets from patients with type 2 diabetes
compared with non-diabetic individuals [5]. Moreover, the
type 2 diabetic islets showed reduced PGC-1α mRNA
levels in parallel with decreased glucose-stimulated insulin
secretion. PGC-1α is a transcriptional co-activator that
stimulates mitochondrial oxidative metabolism and thereby
ATP production. Our study suggests that DNA methylation
can regulate gene expression in pancreatic islets from
patients with type 2 diabetes and subsequently contribute
to impaired insulin secretion [5].
Although previous studies have found the insulin gene to
be regulated by epigenetic mechanisms, it is not clear
whether epigenetic alterations of the insulin gene are
involved in the pathogenesis of impaired insulin secretion
in type 2 diabetes [6–8]. A recent study proposed that
insulin gene expression is regulated by DNA methylation
[9]. Kuroda and co-workers showed that while the degree
of DNA methylation is low in the insulin promoter of beta
cells, the same promoter is highly methylated in other cell
types. By using the insulin promoter in a luciferase
expression assay, they further proposed that a high degree
of DNA methylation is associated with low gene expres-
sion. However, it is not known whether DNA methylation
of the insulin promoter differs between pancreatic islets
from patients with type 2 diabetes and those from non-
diabetic individuals. The aim of the present study was to
examine DNA methylation of the insulin promoter in
pancreatic islets from 48 non-diabetic and nine type 2
diabetic human donors and to relate the degree of DNA
methylation to insulin gene expression, HbA1c levels, BMI
and age. We separately analysed insulin promoter DNA
methylation in beta and alpha cells isolated from human
pancreatic islets as well as in clonal rat beta cells exposed
to hyperglycaemia.
Methods
Pancreatic islets Pancreatic islets from 48 non-diabetic and
nine type 2 diabetic deceased donors were obtained from
the Human Tissue Laboratory at Lund University Diabetes
Centre (Table 1). Islets were prepared by collagenase
digestion and density gradient purification. After isolation,
islets were cultured free floating in CMRL 1066 culture
medium (ICN Biomedicals, Costa Mesa, CA, USA)
supplemented with 10 mmol/l HEPES, 2 mmol/lL-gluta-
mine, 50 μg/ml gentamicin, 0.25 μg/ml Fungizone (GIBCO
BRL, Gaithersburg, MD, USA), 20 μg/ml ciprofloxacin
(Bayer Healthcare, Leverkusen, Germany), and 10 mmol/
l nicotinamide at 37°C (5% CO2) prior to RNA and DNA
preparation. The islet purity was similar for type 2 diabetic
(68±19%) and non-diabetic (58.7±19%, p=0.16) donors.
Insulin content in homogenised human islets was assessed
by ELISA (Mercodia, Uppsala, Sweden) and values were
normalised to the total DNA in each sample as determined
by a fluorometric assay (Quant-iT Picogreen, Invitrogen
Molecular Probes, Stockholm, Sweden). Glucose-
stimulated insulin secretion from the human islets was
measured in vitro in static incubations as previously
described by Rosengren et al. [10]. The donor before death
or her/his relatives had, on admission to the intensive care
unit, given their consent to donate organs. The local ethics
committees approved the protocols.
Beta cell purification Beta and alpha cells were purified
from pancreatic islets of three human donors (aged 54, 55
and 74 years, with BMI 21.5–23.1 kg/m
2), different from
the donors described in Table 1, using a method
previously described by Parnaud et al. [11]. Dissociation
of islet cells was achieved by incubation with constant
agitation for 3 min at 37°C in 0.05% (wt/vol.) trypsin-
EDTA (Invitrogen) supplemented with 3 mg/ml DNAse I
(Roche, Basel, Switzerland) followed by vigorous pipet-
ting. Labelling and FACS sorting of the beta and alpha cell
fractions was performed as previously described by
Parnaud et al. [11]. Sorted alpha and beta cells were
applied to microscope slides and co-immunostained for
insulin and glucagon in order to detect the amount of alpha
cells in the beta cell fraction, and vice versa. Using this
method, a beta cell purity of 89±9% (mean±SD) was
achieved [12].
Cell culture Clonal rat insulinoma-derived INS 832/13 beta
cellswereculturedinRPMImediumwith11.1mmol/lglucose,
which is the basal glucose concentration for these cells,
supplemented with 10% fetal calf serum, 1 mmol/l sodium
pyruvate, 10 mmol/l HEPES, 50 μmol/l β-mercaptoethanol,
100 U/ml penicillin and 100 μg/ml streptomycin at 37°C in a
humidified atmosphere containing 95% air and 5% CO2.
The cells were plated out in six well plates and allowed to
attach overnight. The medium was then replaced with fresh
medium containing either 11.1 or 16.7 mmol/l glucose. The
cells were further cultured for 72 h, with the medium
exchanged after 48 h. DNA was isolated with the All Prep
kit (Qiagen, Hilden, Germany) and kept at −20°C until
analysis.
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human islets using All Prep DNA/RNA kit and cDNA was
synthesised using QuantiTect Reverse Transcription kit
(Qiagen, Hilding, Germany). Insulin mRNA levels were
analysed using TaqMan Real-Time PCR with an ABI Prism
7900 HT system and gene-specific probes and primer pairs
(Assays-on-demand, Hs02741908_m1; Applied Biosys-
tems, Foster City, CA, USA). The insulin transcript level
was normalised to the mRNA level of cyclophilin A
(4326316E, Applied Biosystems) and quantified using the
ΔΔCt method.
DNA methylation analysis Sequenom’s MassARRAY Epi-
TYPER protocol was applied to measure DNA methylation
(Sequenom, San Diego, CA, USA). Five different Epi-
TYPER assays were designed (EpiDesigner), covering 26
CpG sites of the human insulin promoter (successful data
were generated for 25 CpG sites, see below). Also, two
assays covering ten CpG sites of the rat insulin promoter
were designed (successful data were generated for five CpG
sites, see below). The primer sequence and the location of
the five human assays and the two rat assays are given in
Electronic supplementary material (ESM) Table 1. Ge-
nomic DNA was first extracted from the human islets and
the clonal rat beta cells using the All Prep DNA/RNA kit
(Qiagen) as well as from whole blood cells using the Gentra
Puregene Blood Kit (Qiagen). Genomic DNA, 500 ng, was
bisulfite treated with the EZ DNA Methylation kit (Zymo
Research, Orange, CA, USA). Duplicate PCR reactions
were performed with bisulfite-specific PCR primers con-
taining a T7-promotor tag and a 10mer tag on the reverse
and forward primer, respectively. In vitro transcription and
RNase cleavage reaction were conducted using the Mas-
sCleave (hMC) kit according to the manufacturer’sr e c o m -
mendations. The cleavage reaction was dispensed onto a 384
element SpectroCHIP bioarray and mass spectra were
acquired using a MassARRAY mass spectrometer. The
spectra were analysed and the methylation ratios were
obtained by the EpiTYPER software v.1.0.1. As a result of
the cleavage pattern, four CpG sites were analysed as two
separate CpG units (CpG −1,478 together with CpG −1,482
andCpG−1,893togetherwithCpG−1,897).Theresultsfrom
these CpG units were excluded from further statistical
analysis. CpG site −1,565 was excluded from this study
because of variation between duplicate samples. CpG site
−180 did not generate any methylation data using the
EpiTYPER because of low mass of the cleavage product.
However, as CpG −180 has previously been suggested to be
important for regulation of insulin gene expression via
activating transcription factor 2 (ATF2, also known as cAMP
responsive element binding protein 2 [CREB2]) binding [9],
we used Pyrosequencing (Qiagen) according to manufac-
turer’s recommendations to analyse DNA methylation at
CpG −180 (ESM Table 1). Five CpG sites in the rat insulin
promoter assay did not generate any methylation data due to
either low or high mass of the cleavage product.
Statistical analysis Differences in DNA methylation of the
insulin promoter between type 2 diabetes patients and non-
diabetic individuals were analysed using multivariate regres-
sion analysis including disease status, age, sex and BMI as
covariates. Correlations were calculated using the Spearman
correlation coefficient. Paired tests were used to analyse
differences between beta and alpha cells as well as between
clonal rat beta cells cultured in 11.1 or 16.7 mmol/l glucose.
Non-parametric two-sample tests were used to analyse differ-
ences in insulin mRNA and content as well as glucose-
stimulated insulin secretion between individuals with type 2
diabetes and non-diabetic donors. All p values were two-
tailed and p values less than 0.05 were considered
significant. The presented p values have not been corrected
for multiple testing. Statistical calculations were performed
using NCSS software (NCSS Statistical Software, Kaysville,
UT, USA).
Results
Human pancreatic islets from nine donors with type 2
diabetes and 48 non-diabetic donors were included in this
study (Table 1). Insulin mRNA expression, insulin content
and glucose-stimulated insulin secretion were decreased in
pancreatic islets from individuals with type 2 diabetes
compared with those from non-diabetic donors (58%
decrease, p=0.002; 57% decrease, p=0.004; and 26%
decrease, p=0.04; respectively, Fig. 1). Moreover, the
insulin mRNA level correlated positively with insulin
content in these islets (rho=0.49, p=0.0004). DNA
methylation levels were obtained for 25 CpG sites covering
2,518 bp of the human insulin promoter in the same set of
human pancreatic islets (Fig. 2a,b, Table 1 and ESM
Table 1). Four CpG sites, located 234, 180, 102 bp
upstream (CpG −234, −180, −102) and 63 bp downstream
(CpG +63) of the transcription start site, respectively,
showed increased DNA methylation in islets from patients
Table 1 Characteristics of human pancreatic donors
Characteristic Type 2 diabetic
donors
Non-diabetic
donors
p value
n (male/female) 9 (5/4) 48 (26/22)
Age (years) 57.0±13.1 56.7±10.1 0.9
BMI (kg/m
2) 28.5±4.7 25.4±3.1 0.08
HbA1c 7.3±1.2 5.7±0.8 0.0001
Data are expressed as mean±SD
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(7.8%, p=0.03; 7.1%, p=0.02; 4.4%, p=0.03 and 9.3%, p
=0.03, respectively, Fig. 3a–d). We next examined whether
the degree of methylation of CpG −234, −180, −102 and
+63 correlated with insulin gene expression and HbA1c
levels in all studied individuals. While insulin mRNA
expression correlated negatively, the level of HbA1c
correlated positively with DNA methylation at three out
of four sites: CpG −234, −180 and +63 (Fig. 4a–d, Fig. 5a–
d). By in silico analysis, the 2,518 bp of the insulin
promoter sequence was examined for putative transcription
factor binding sites (TFBS) using an algorithm from
Genomatix (www.genomatix.de, accessed 28 September
2009). Both previously known and putative TFBS that co-
localise with the analysed CpG sites are shown in Fig. 2a.
Although there was no significant difference in DNA
methylation in islets from type 2 diabetic donors compared
with non-diabetic donors for the additional CpG sites
analysed, the percentage of DNA methylation correlated
negatively with insulin mRNA expression for a number of
CpG sites, including CpG −19 (ρ=−0.65, p<1×10
−6), CpG
−69 (ρ=−0.70, p<1×10
−6), CpG −135 (ρ=−0.58, p=3×
10
−6), CpG −206 (ρ=−0.64, p<1×10
−6), CpG −982 (ρ=
−0.62, p<1×10
−6), CpG −1,014 (ρ=−0.42, p=0.001), CpG
−1,695 (ρ=−0.32, p=0.01), CpG −1,926 (ρ=−0.53, p=3×
10
−5) and CpG −2,254 (ρ=−0.51, p=6×10
−6). While both
HbA1c levels and BMI correlated negatively with insulin
mRNA expression (ρ=−0.39, p=0.008 and ρ=−0.26, p=
0.058, respectively), they correlated positively with the level
of DNA methylation for a number of insulin CpG sites
(HbA1c CpG −19, −69, −135, −206, −982, −1,527, −2,252,
ρ=0.29–0.40, p<0.05; and BMI CpG +63, −69, −135, −180,
−982, –1,014, −1,527, −1,582, −1,602, −1,695, −1,926, ρ=
0.26–0.40, p<0.05). However, there was no significant
positive correlation between age and DNA methylation of
the insulin promoter.
In order to examine if hyperglycaemia affects insulin
promoter DNA methylation specifically in beta cells, we
cultured clonal rat insulinoma-derived INS 832/13 beta
cells in the presence of either basal (11.1 mmol/l) or high
(16.7 mmol/l) levels of glucose for 72 h and measured
DNA methylation for five CpG sites of the rat insulin
promoter. Hyperglycaemia increased DNA methylation
significantly for two specific CpG sites located 1,057 bp
upstream of the transcription start site (TSS) (CpG −1,057,
12.7% increase, p=0.005) and 58 bp downstream of the
TSS (CpG +58, 5.0% increase, p=0.03) in the clonal rat
beta cells (Fig. 5e). Furthermore, the average DNA
methylation of the studied insulin promoter region in-
creased in rat clonal beta cells exposed to hyperglycaemia
(8.3% increase, p=0.047, Fig. 5e).
We proceeded to compare the overall DNA methylation
patterns in human pancreatic islets and blood cells. In
human pancreatic islets, the methylation level of the
analysed CpG sites varied according to the distance from
the TSS. In general, CpG sites located closer to the TSS
showed lower levels of DNA methylation compared with
CpG sites located further upstream (5′) (Fig. 2b). Indeed,
the average methylation level for CpG sites +63 to −234
was significantly lower than the average methylation level
for CpG sites −982 to −2,266 (34.3±11.5% vs 73.9±
12.4%, p<0.0001). In contrast, in blood cells DNA
methylation was high throughout the analysed insulin
promoter and for the majority of CpG sites the methylation
level was higher in blood than in human islets (Fig. 2b).
Moreover, when comparing insulin promoter DNA meth-
ylation in beta and alpha cells isolated from human
pancreatic islets, five out of eight analysed CpG sites
showed lower methylation in beta than in alpha cells (p<
0.05) (Fig. 2c).
Finally, as it has been proposed that CpG sites close to
each other show a similar degree of methylation within a
tissue and individual, we also tested if the percentage of
insulin promoter methylation of the analysed CpG sites
correlated in the pancreatic islets. Indeed, the degree of
methylation correlated for the majority of analysed CpG
sites, i.e. all the first eight CpG sites analysed correlated
positively, including CpG +63, −19, −69, −102, −135,
−180, −206, −234 (ρ=0.66–0.91, p<1×10
−6).
Discussion
This study proposes that DNA methylation affects insulin
mRNA expression levels in human pancreatic islets. Four
CpG sites, located 234, 180, 102 upstream (5′) and 63 bp
downstream (3′) of the transcription start site of the insulin
gene (CpG −234, −180, −102 and +63), had a higher
degree of DNA methylation in islets from type 2 diabetes
Fig. 1 Insulin mRNA levels, insulin content and glucose-stimulated
insulin secretion measured in human pancreatic islets. Pancreatic islets
from patients with type 2 diabetes show decreased (a) relative insulin
mRNA levels, (b) insulin content and (c) glucose-stimulated insulin
secretion, compared with non-diabetic control donors. Results are
expressed as mean±SEM. *p<0.05 vs control islets. Control, non-
diabetic donors; GSIS, glucose-stimulated insulin secretion; T2D,
donors with type 2 diabetes
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DNA methylation of the insulin promoter inversely
correlated with lower insulin mRNA levels. Moreover,
both insulin mRNA expression and insulin content as well
as glucose-stimulated insulin secretion were decreased in
islets from type 2 diabetic donors.
Previous studies together with the present study show
that differences in DNA methylation between type 2
diabetic patients and non-diabetic controls are less than
10% [4, 5]. Type 2 diabetes is a polygenic disease and it is
possible that the effects of DNA methylation on type 2
diabetes are similar to those seen in genetic studies, where
multiple loci with small effect sizes together contribute to
an increased risk for disease [13–16]. One limit with our
study is the small number of diabetic islets, and replication
studies in other cohorts are needed to confirm our results.
Future genome-wide methylation studies with larger num-
ber of patients are further required to dissect the role of
Fig. 2 DNA methylation of the
insulin promoter. (a) A schema-
tic representation of 2,518 bp of
the insulin gene region analysed
for DNA methylation. Positions
of CpG sites in relation to the
TSS are indicated: black circles
represent analysed CpG sites,
grey circles are not analysed.
Putative and previously known
transcription factor binding sites
that co-localise with a CpG site
are indicated. DNA methylation
levels in percentage are analysed
in (b) human pancreatic islets
from 48 controls (white bars)
and nine type 2 diabetic patients
(black bars) as well as in five
blood samples (grey bars; one
man and four women,
29–57 years) and (c) beta cells
(white bars) and alpha cells
(black bars) isolated from pan-
creatic islets of three human
donors. Results are expressed as
mean±SEM, and have not been
corrected for multiple testing.
†p<0.05 vs control islets,
*p<0.05 vs control islets.
BACH2, basic leucine zipper
transcription factor 2; COUP,
chicken ovalbumin upstream
promoter; HNF4, hepatocyte
nuclear factor 4; PDX1,
pancreatic and duodenal
homeobox 1; ISL1, islet 1;
EVX1/2, even-skipped
homeobox 1/2; MARE, Maf
recognition element; NR2C1/2,
nuclear receptor subfamily 2,
group C, member 1/2; PTF1,
pancreas specific transcription
factor, NEUROD1, neurogenic
differentiation 1
364 Diabetologia (2011) 54:360–367DNA methylation in islets from individuals with type 2
diabetes.
Interestingly, elevated HbA1c levels were associated with
increased DNA methylation of the human insulin promoter.
Recent studies have demonstrated that hyperglycaemia may
induce epigenetic changes and thereby increase expression
of pro-inflammatory genes in vascular cells, which subse-
quently may increase the risk for diabetic complications
[17–20]. It is possible that hyperglycaemia also induces
epigenetic changes, e.g. increases DNA methylation, in the
insulin promoter of human beta cells, resulting in reduced
insulin expression. Indeed, our data support such a
hypothesis; we found that hyperglycaemia for 72 h in-
creased insulin promoter DNA methylation in clonal rat
beta cells. Although we cannot rule out that the changes we
Fig. 5 Impact of hyperglycaemia on insulin promoter DNA methyl-
ation at (a) CpG site −234, (b) CpG site −180, (c) CpG site −102 and
(d) CpG site +63. The HbA1c level correlates positively with insulin
promoter DNA methylation at (a) CpG site −234 (ρ=0.36, p=0.01),
(b) CpG site −180 (ρ=0.42, p=0.004) and (d) CpG site +63 (ρ=0.44,
p=0.002), while borderline significance was established for (c) CpG
site −102 (ρ=0.28, p=0.056) in human pancreatic islets. (e) Clonal rat
beta cells cultured in 16.7 mmol/l glucose showed increased insulin
promoter DNA methylation of CpG sites −1,057 and +58 and a
significant increase was also seen for the average DNA methylation
measured across the studied region compared with beta cells cultured
in 11.1 mmol/l glucose. Results are expressed as mean±SEM. *p<0.05,
**p<0.01. Black bars, beta cells cultured in 16.7 mmol/l glucose; white
bars, beta cells cultured in 11.1 mmol/l glucose
Fig. 4 Correlations between the level of insulin mRNA expression
and insulin promoter DNA methylation in human pancreatic islets.
The relative insulin mRNA expression correlates negatively with
insulin promoter DNA methylation at (a) CpG site −234 (ρ=−0.64, p
<1×10
−6), (b) CpG site −180 (ρ=−0.66, p<1×10
−6) and (d) CpG site
+63 (ρ=−0.72, p<1×10
−6), while borderline significance was
established for (c) CpG site −102 (ρ=−0.25, p=0.065)
Fig. 3 Impact of type 2 diabetes on DNA methylation of the insulin
promoter. Pancreatic islets from nine patients with type 2 diabetes show
elevated insulin promoter DNA methylation in (a) CpG site −234, (b)
CpG site −180, (c) CpG site −102 and (d) CpG site +63, compared with
48 non-diabetic donors. Results are expressed as mean±SEM and have
not been corrected for multiple testing. *p<0.05. Control, non-diabetic
donors; T2D, donors with type 2 diabetes
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diabetic islets are due to altered cell composition in islets
from type 2 diabetic donors, our data from the clonal rat
beta cells demonstrate that hyperglycaemia specifically
increases insulin promoter DNA methylation in beta cells.
Age and obesity are important risk factors for type 2
diabetes. Although our previous studies have shown that
ageing is associated with increased DNA methylation
and reduced gene expression of type 2 diabetes
candidate genes in human skeletal muscle, we did not
find any correlation between age and DNA methylation
of the insulin promoter in pancreatic islets [1, 3].
Nevertheless, a lack of correlation between age and DNA
methylation could reflect the small number of young
donors included in this study, as only three donors were
younger than 40 years. However, increased BMI was
associated with reduced insulin expression and increased
DNA methylation, suggesting that obesity may increase
methylation of the insulin promoter.
Two studies have recently analysed histone modifica-
tions and DNA methylation of the insulin gene in human
pancreatic islets and in isolated pancreatic beta cells [8, 9].
They investigated islets from a small number of donors, and
no islets from type 2 diabetic patients were included. In
agreement with our data, they found lower levels of DNA
methylation in pancreatic islets compared with other cell
types. Interestingly, when we analysed DNA methylation in
isolated human beta cells we found, on average, 19% DNA
methylation, demonstrating that the insulin promoter of
isolated beta cells is not completely unmethylated. More-
over, when Kuroda and co-workers performed chromatin
immunoprecipitation (ChIP) experiments in cells trans-
fected with either methylated or unmethylated insulin
promoter sequences, they found that methylation inhibited
binding of ATF2 to the insulin promoter and it increased
binding of a methyl-binding protein, methyl CpG binding
protein 2 (MeCP2), which is associated with reduced
transcription [9]. Together, these studies suggest that DNA
methylation can regulate insulin expression in beta cells.
However, factors additional to our observed changes in
DNA methylation in type 2 diabetic islets could contribute
to the changes found in insulin gene expression. It has been
proposed that DNA methylation of CpG sites close to each
other show a similar degree of methylation. Although our
study supports this theory, the mechanisms behind this
phenomenon are unknown.
In conclusion, four CpG sites within the insulin promoter
show increased DNA methylation in pancreatic islets from
patients with type 2 diabetes compared with non-diabetic
donors. Moreover, hyperglycaemia may increase insulin
promoter DNA methylation in beta cells. Our study further
suggests that DNA methylation can influence insulin gene
expression in human pancreatic islets.
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